British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato…